一品红：获得甲硫酸新斯的明注射液药品注册证书

Core Viewpoint - Yipin Hong (300723) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Chloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Company Summary - The approved product, Methacholine Chloride Injection, is indicated for the antagonism of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, as well as for conditions such as myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - According to data from Minet, the sales scale of Methacholine Chloride in urban and county-level public hospitals in China is projected to be approximately 791 million yuan in 2024 [1]